Safe and Timely Antithrombotic Removal (STAR) Registry
Launched by CYTOSORBENTS, INC · Sep 30, 2021
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The STAR Registry is a clinical study that aims to understand how well a treatment called CytoSorb works in removing blood-thinning medications (antithrombotics) from patients who have experienced bleeding during or after surgery. The goal is to collect real-world data about how often this treatment is used and what outcomes patients experience. Researchers are currently looking for participants aged 65 and older who are willing to consent to joining this registry.
If you or a loved one are eligible to participate, you would be involved in monitoring how CytoSorb is used to help manage your treatment during your recovery. Participation involves agreeing to have your health information collected and analyzed to help improve future care for patients in similar situations. It’s important to note that this study is only for those using CytoSorb specifically for removing blood thinners, not for any other purpose.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CytoSorb utilization for antithrombotic removal
- • Informed consent for prospective registry participation
- Exclusion Criteria:
- • • Use of CytoSorb for purpose other than antithrombotic removal
About Cytosorbents, Inc
Cytosorbents, Inc. is a pioneering medical technology company focused on developing innovative therapies for critical care and inflammatory conditions. Specializing in blood purification and organ support, the company’s flagship product, CytoSorb®, utilizes a proprietary adsorbent technology to remove harmful substances from the bloodstream, thereby improving patient outcomes in various acute and chronic diseases. With a commitment to advancing scientific research and clinical applications, Cytosorbents is dedicated to enhancing the standard of care through rigorous clinical trials and collaborations with healthcare professionals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, , Germany
Zürich, , Switzerland
Vienna, , Austria
Hannover, , Germany
Bruxelles, , Belgium
Innsbruck, , Austria
Lund, , Sweden
Ulm, , Germany
Trier, , Germany
Sheffield, , United Kingdom
Ghent, , Belgium
Liège, , Belgium
Nürnberg, , Germany
Essen, Nordrhein Westfalen, Germany
Hamburg, , Germany
Coswig, , Germany
Ulm, Baden Württemberg, Germany
Klagenfurt, , Austria
Oldenburg, , Germany
Munich, , Germany
Geneva, , Switzerland
Graz, , Austria
Heidelberg, Baden Württemberg, Germany
Erlangen, Bavaria, Germany
München, Bavaria, Germany
London, , United Kingdom
Coswig, , Germany
Erlangen, , Germany
Heidelberg, , Germany
München, , Germany
Aalst, , Belgium
Kiel, , Germany
Heidelberg, , Germany
Munich, , Germany
Coswig, , Germany
Leipzig, , Germany
Blackpool, , United Kingdom
Patients applied
Trial Officials
Michael Schmoeckel, Prof, MD
Principal Investigator
LMU Klinikum Großhadern
Robert Storey, Prof, BSc
Principal Investigator
University of Sheffield
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials